Skip to main content

Advertisement

Table 2 Clinical responses of study groups to lixisenatide add-on treatment to basal insulin therapy ± oral antidiabetic drugs

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

Subgroups BMI <25 kg/m2 BMI 25–<30 kg/m2 BMI 30–<35 kg/m2 BMI ≥35 kg/m2 p value
HbA1c,  % (SD)
 Baseline 8.23 (0.81) 8.24 (0.82) 8.06 (0.92) 8.06 (0.84) 0.07*
 Week 24 7.61 (1.25) 7.56 (1.17) 7.38 (1.07) 7.33 (1.09) 0.10*
 Mean change from baseline −0.63 (1.19) −0.68 (1.08) −0.68 (0.92) −0.73 (0.92) 0.88*
Patients with endpoint HbA1c n (%) 0.09**
 <7 % 47 (35.3) 77 (34.7) 69 (41.6) 66 (46.8)  
 ≥7 % 86 (64.7) 145 (65.3) 97 (58.4) 75 (53.2)  
FPG mg/dL (SD)  
 Baseline 129.2 (41.1) 133.7 (44.2) 136.5 (40.7) 137.7 (41.7) 0.35*
 Week 24 132.5 (46.9) 135.4 (54.2) 132.7 (42.5) 135.6 (45.3) 0.90*
 Mean change from baseline 3.2 (52.7) 1.7 (59.8) −3.9 (46.6) −2.1 (40.8) 0.60*
Patients with endpoint FPG n (%) 0.63**
 <110 mg/dL 48 (36.6) 81 (37.2) 54 (32.5) 44 (31.7)  
 ≥110 mg/dL 83 (63.4) 137 (62.8) 112 (67.5) 95 (68.4)  
PPG mg/dL (SD)a  
 Baseline 301.5 (75.2) 287.5 (77.3) 279.0 (82.2) 252.6 (75.2) <0.0001*
 Week 24 175.0 (86.8) 184.7 (83.8) 197.3 (82.0) 185.5 (68.9) 0.15*
 Mean change from baseline −126.6 (109.7) −103.5 (109.2) −82.0 (103.1) −67.2 (84.0) <0.0001*
 Percent change from baseline −42 % −36 % −29 % −27 %  
Basal insulin dose U (SD)  
 Baseline 26.2 (11.6) 36.5 (15.5) 50.3 (24.8) 63.9 (41.2) <0.0001*
 Week 24 25.5 (12.1) 36.2 (17.0) 50.4 (26.1) 62.1 (31.6) <0.0001*
 Mean change from baseline −0.7 (4.8) −0.3 (6.8) 0.2 (10.0) −1.8 (29.8) 0.72*
Body weight kg (SD)  
 Baseline 61.0 (9.0) 73.8 (9.9) 88.9 (11.8) 110.4 (18.6) <0.0001*
 Week 24 60.8 (9.3) 73.1 (10.0) 87.9 (12.2) 109.4 (19.1) <0.0001*
 Mean change from baseline −0.2 (2.0) −0.7 (2.4) −1.0 (3.3) −1.0 (3.5) 0.06*
BMI kg/m2 (SD)  
 Baseline 23.1 (1.5) 27.6 (1.5) 32.4 (1.4) 40.3 (5.0)  
 Week 24 23.1 (1.7) 27.4 (1.7) 32.0 (1.8) 39.9 (5.3) <0.0001*
 Mean change from baseline −0.1 (0.8) −0.2 (0.9) −0.4 (1.2) −0.4 (1.3) 0.07*
  1. BMI body mass index, FPG fasting plasma glucose, PPG postprandial blood glucose
  2. Data are mean (SD = standard deviation) unless otherwise stated
  3. a2 h after a standardized meal test
  4. * Statistical significance of differences was determined by ANOVA
  5. ** Statistical significance of differences was determined by χ2 test